-
Pfizer will likely have millions of coronavirus vaccine doses ready by the end of 2020 — and the company’s CEO is willing to be one of the first to take it.
The Manhattan-based drugmaker
-
President-elect Joe Biden's health care advisers met with drug companies before last week's election about their efforts to produce coronavirus vaccines and treatments, a new report says.
-
The prediction was the latest suggestion from a major drugmaker that the race to produce a vaccine for the deadly COVID-19 bug could reach a significant milestone in the coming months.
-
AstraZeneca’s coronavirus vaccine could still be ready this year even though it had to halt a key clinical study after a participant got sick, CEO Pascal Soriot said Thursday. The British pharmaceutical firm should know by the end of 2020 whether the vaccine protects patients from the virus if it’s able to resume the study …
-
Nine drugmakers pledged Tuesday to make safety their top priority as they race to develop a vaccine for the deadly coronavirus — vowing they would not seek emergency authorization before large-scale Phase 3 clinical trials are completed. The biopharma firms said in a joint statement that they would follow “high ethical standards and sound scientific …
-
Pharmacy giants and tech titans are in a crowded battle to deliver your prescriptions — but a startup coming off a coronavirus-fueled growth spurt thinks it can beat them. Consumers wary of waiting in packed drugstores have turned to digital pharmacy services like Capsule, a New York-based company that’s seen a surge of new customers …
-
Shares of German biotechnology firm CureVac nearly tripled in their Nasdaq debut Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus. The stock opened at $44 per share, up from the initial public offering price of $16 per share. CureVac, backed by Microsoft founder and …
-
Americans likely won’t have to pay for a coronavirus vaccine once researchers have one ready, according to reports. The US government plans to pick up the tab for the hundreds of millions of vaccine doses that pharmaceutical firms are racing to produce, the Wall Street Journal reported. The feds are also reportedly talking with insurance …
-
The United States has entered an agreement with drugmaker Moderna Inc to acquire 100 million doses of its potential COVID-19 vaccine for around $1.5 billion, the company and White House said on Tuesday. The United States in recent weeks has made deals to acquire hundreds of millions of doses of potential COVID-19 vaccines from several companies …
-
Johnson & Johnson kicked off human trials of its experimental COVID-19 vaccine Thursday, after the shots already proved successful in protecting monkeys, the drugmaker announced. Company honchos pointed to a new study which found that five out of six primates who got the single-dose shot were protected from infection when exposed to the coronavirus, as …
Pfizer will likely have millions of coronavirus vaccine doses ready by the end of 2020 — and the company’s CEO is willing to be one of the first to take it. The Manhattan-based drugmaker
